Data coverage, completeness and provenance for NEUREN PHARMACEUTICALS LIMITED in the Stock Market API — Health Care · Biotechnology.
Source date: 2026-10-30T05:10:11. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-10-30 | 20.3600 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-29 | 20.1400 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-28 | 18.9500 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-27 | 18.7000 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-26 | 18.6500 | AUD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/NEU/prices · Price parameters and adjustment semantics
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Website: https://www.neurenpharma.com · Profile fields populated: 60%
Share of stored fields populated in the anchor reporting period (FY2025), primary source yfinance. Full per-field breakdown: GET /api/v1/companies/NEU/financials.
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2025 (AUD) | 2025-12-31 | 26 | yfinance | ||||
| FY2024 (AUD) | 2024-12-31 | 25 | yfinance | ||||
| FY2023 (AUD) | 2023-12-31 | 26 | yfinance | ||||
| FY2022 (AUD) | 2022-12-31 | 26 | yfinance |
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/NEU
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/NEU/financials
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/NEU/metrics/summary
Report PDFs with LLM-ready markdown conversions where available.
GET /api/v1/companies/NEU/filings
Dated press releases and announcements with source links.
GET /api/v1/companies/NEU/news
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/NEU
Free tier — instant API key. Built for AI agents.